New pill shows promise in controlling rare blood cancer
NCT ID NCT02180724
Summary
This study tested a daily oral medication called acalabrutinib for people with Waldenström macroglobulinemia, a rare type of blood cancer. It involved 107 adults, including those whose cancer returned after prior treatment and some newly diagnosed patients. The main goal was to see how well the drug controls the disease and how safe it is for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTRÖM MACROGLOBULINEMIA (WM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Santa Barbara, California, 93105, United States
-
Research Site
Aurora, Colorado, 80012, United States
-
Research Site
Washington D.C., District of Columbia, 20007, United States
-
Research Site
Minneapolis, Minnesota, 55404, United States
-
Research Site
New York, New York, 10021, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Austin, Texas, 78705, United States
-
Research Site
Bedford, Texas, 76022, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Vancouver, Washington, 98684, United States
-
Research Site
Aurillac, 15002, France
-
Research Site
Clermond Ferrand, 63003, France
-
Research Site
Marseille, 13273, France
-
Research Site
Montpellier, 34295, France
-
Research Site
Nantes, 44093, France
-
Research Site
Paris, 75015, France
-
Research Site
Paris, 75651, France
-
Research Site
Pierre-Bénite, 69495, France
-
Research Site
Poitiers, 86021, France
-
Research Site
Reims, 51092, France
-
Research Site
Rennes, 35000, France
-
Research Site
Toulouse, 31059, France
-
Research Site
Vandœuvre-lès-Nancy, 54500, France
-
Research Site
Athens, 11528, Greece
-
Research Site
Bologna, 40138, Italy
-
Research Site
Milan, 20162, Italy
-
Research Site
Novara, 28100, Italy
-
Research Site
Amsterdam, 1105AZ, Netherlands
-
Research Site
Utrecht, 2508GA, Netherlands
-
Research Site
Salamanca, 37007, Spain
-
Research Site
Bournemouth, BH7 7DW, United Kingdom
-
Research Site
Leeds, LS9 7TF, United Kingdom
-
Research Site
Leicester, LE1 7RH, United Kingdom
-
Research Site
London, NW1 2BU, United Kingdom
-
Research Site
London, SW3 6JJ, United Kingdom
-
Research Site
Oxford, OX3 7LE, United Kingdom
-
Research Site
Plymouth, PL6 8DH, United Kingdom
-
Research Site
Southampton, SO16 6YD, United Kingdom
Conditions
Explore the condition pages connected to this study.